Fate Therapeutics to Present at Upcoming Investor Conferences
Fate Therapeutics (NASDAQ: FATE) announced its participation in two upcoming investor conferences. The Barclays Global Healthcare Conference is scheduled for March 11, 2021, from 11:30 AM to 11:55 AM ET, followed by the Oppenheimer Virtual 31st Annual Healthcare Conference on March 17, 2021, from 1:10 PM to 1:40 PM ET. Both presentations will be available via live webcast on the Company's website under 'Events & Presentations.' Fate Therapeutics focuses on cellular immunotherapies for cancer and is currently developing innovative therapies including natural killer cell and T-cell immunotherapies.
- None.
- None.
SAN DIEGO, March 08, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, announced today that the Company will present at the following upcoming investor conferences:
- Barclays Global Healthcare Conference on Thursday, March 11, 2021 from 11:30-11:55AM ET
- Oppenheimer Virtual 31st Annual Healthcare Conference on Wednesday, March 17, 2021 from 1:10-1:40PM ET
A live webcast, if recorded, of each presentation can be accessed under "Events & Presentations" in the Investors section of the Company's website at www.fatetherapeutics.com. The archived webcast will be available on the Company's website shortly after the event.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Company’s immuno-regulatory product candidates include ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease. Fate Therapeutics is headquartered in San Diego, CA.
Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
christina@sternir.com
FAQ
When will Fate Therapeutics present at the Barclays Global Healthcare Conference?
What is the date and time for Fate Therapeutics at the Oppenheimer Virtual 31st Annual Healthcare Conference?
How can I access Fate Therapeutics' investor conference presentations?
What are the main areas of focus for Fate Therapeutics?
What is the stock symbol for Fate Therapeutics?
